



Home : Aisling Capital : Life Sciences Private Equity































Toggle navigation



















Developing Treatments for Food Allergies Using Standardized, Pharmaceutical-Grade Food Allergens and Characterized Oral Desensitization Immunotherapy

Learn More About Aimmune










Innovative medicines for the treatment of hormonally-driven cancers.
Aisling congratulates the management teams of Aragon and Seragon on their recent acquisitions by Johnson & Johnson and Genentech, respectively.
learn moreLearn More About Aragon & Seragon










CoolSculpting®: more science, less fat.
Aisling congratulates the management team of Zeltiq on its recent acquisition by Allergan.
Learn More About Zeltiq










Largest provider of biopharmaceutical development and commercial outsourcing services.

Learn More About Quintiles










Dalvance™ for the treatment of acute bacterial skin and skin structure infections.
Aisling congratulates the management team of Durata on its recent acquisition by Actavis.
Learn More About Durata










Diagnostics to accurately identify sepsis pathogens in hours instead of days.

Learn More About T2 Biosystems









T2 Biosystems










Aragon & Seragon








Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.







Meet Our Team
A combined 150+ years of experience in the healthcare industry.
learn more







See Our Portfolio
$1.8 billion in assets, with a track record of investing and returning capital since 2000.
learn more








Latest News



T2 Biosystems Receives CE Mark for T2Bacteria™ Panel Enabling Commercialization in Europe
July 18, 2017
LEXINGTON, Mass., July 18, 2017 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products to improve patient health, announced today that it has received a CE…
READ MORE


Menlo Therapeutics Raises $50M
July 18, 2017
MENLO PARK, Calif., July 18, 2017 /PRNewswire/ -- Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment…
READ MORE


Paratek Announces Phase 3 Study of Oral-Only Dosing of Omadacycline Met All Primary and Secondary FDA and EMA Efficacy Endpoints in Acute Bacterial Skin Infections
July 17, 2017
BOSTON, July 17, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today positive top-line results from a pivotal Phase 3 clinical study comparing its once-daily, oral investigational antibiotic, omadacycline, to twice-daily oral linezolid…
READ MORE



more news














Team : Aisling Capital : Life Sciences Private Equity






























Toggle navigation










Team


Aisling Capital Team
Aisling Capital is led by a group of investment professionals with diverse backgrounds in
industry, science and finance.
The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.










Steven A. Elms
Managing Partner








Steven A. Elms

Mr. Elms joined Aisling in July of 2000 and currently serves as one of the Managing Partners. Previously, he was a Principal in the Life Sciences Investment Banking Group of H&Q. During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.
Mr. Elms currently serves as a director of ADMA Biologics, EarLens and Loxo Oncology. Previously he served as a director of Advion BioSciences, Ambit Biosciences, Archimica Cooperatief, Avera Pharmaceuticals, Bioenvision, CeNeRx BioPharma, Cidara Therapeutics, LENSAR, NextWave Pharmaceuticals, Novazyme Pharmaceuticals, Pernix Therapeutics, Scerene Healthcare and TRIA Beauty and was Chairman of the Board of Adams Respiratory Therapeutics, MAP Pharmaceuticals and Oculex Pharmaceuticals.
Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.







Andrew Schiff, MD
Managing Partner








Andrew Schiff, MD

Dr. Schiff joined Aisling in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, PowerVision and ZELTIQ Aesthetics, and as a Board observer of Zavante Therapeutics. Prior Board service includes Adams Respiratory Therapeutics, Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra Pharmaceuticals, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix and Quintiles (Board observer). He is a longtime supporter and Board member of the Visiting Nurse Service of New York.
Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.







Dov A. Goldstein, MD
Managing Partner








Dov A. Goldstein, MD

Dr. Goldstein joined Aisling in 2006 and currently serves as one of the Managing Partners. Prior to joining Aisling, Dr. Goldstein served as Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals for five years, up until its acquisition by Pfizer. While at Vicuron Pharmaceuticals, he raised over $250 million in an IPO, PIPE, follow-on and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first U.S. and Italian public-to-public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at Healthcare Ventures. He also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.
Dr. Goldstein currently serves as a director of ADMA Biologics, Cempra Pharmaceuticals and Esperion Therapeutics. Previously, he served as a director of Durata Therapeutics (acquired by Actavis), Loxo Oncology (also served as Chief Financial Officer) and Topaz Pharmaceuticals (acquired by Sanofi) and on other private company Boards.
Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and his B.S. with honors from Stanford University.







Dennis J. Purcell
Founder and Senior Advisor








Dennis J. Purcell

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.
Mr. Purcell received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.







Eric Aguiar, MD
Partner








Eric Aguiar, MD

Dr. Aguiar joined Aisling in 2016. Prior to joining Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million health care focused venture capital and growth equity fund, from 2007-2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a health care venture capital fund, from 2001-2007. He currently sits on the boards of Biohaven and Invitae Corporation.
His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). He was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals). He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.
Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. He received his Medical Degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.







Aftab R. Kherani, MD
Partner








Aftab R. Kherani, MD

Dr. Kherani joined Aisling in 2008 and currently serves as a Partner. Previously, Dr. Kherani was an Engagement Manager for two years at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.
Dr. Kherani currently serves as a director of Spirox and TransEnterix and as a Board observer at ARMGO Pharma, EarLens, Loxo Oncology, Syros Pharmaceuticals and T2 Biosystems.
Dr. Kherani received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient. He also received his B.S. in Biology and A.B. in Economics from Duke, both magna cum laude, graduating Phi Beta Kappa.







Stacey D. Seltzer
Partner








Stacey D. Seltzer

Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.
Ms. Seltzer serves as a director of Aimmune Therapeutics, Miramar Labs and Promentis Pharmaceuticals, and as a Board observer of Prolacta Bioscience. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics (acquired by Actavis) and ZELTIQ Aesthetics. She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant) and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision.
Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.







Josh Bilenker, MD
Operating Partner








Josh Bilenker, MD

Dr. Bilenker joined Aisling in 2006 and currently serves as an Operating Partner. He is President and Chief Executive Officer of Loxo Oncology, an Aisling Capital III portfolio company. Prior to Aisling, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.
Dr. Bilenker currently serves as a director of Loxo Oncology and ViewRay. Previously he served as a director of LENSAR, Roka Bioscience and T2 Biosystems, and as a Board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise.
Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.







Scott Braunstein, MD
Operating Partner








Scott Braunstein, MD

Dr. Braunstein serves as an Operating Partner at Aisling Capital.  He is Senior Vice President, Strategy and Corporate Development at Pacira Pharmaceuticals.  Dr. Braunstein spent 12 years as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. He reviewed pharmaceutical company strategies, business models and management teams, and provided stock recommendations for the J.P. Morgan Asset Equity Group.
Dr. Braunstein serves as a director of Esperion Therapeutics, STAT Medical and the Cornell Alumni Association for the College of Agriculture and Life Sciences.
Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and completed his residency in internal medicine at Cornell University-New York Hospital.  He received his B.S. from Cornell University.







Ayman Sabi
Operating Partner








Ayman Sabi

Mr. Sabi is an independent consultant serving as an Operating Partner at Aisling Capital. He is the founder of SABi Medical Group, B.V., and a seasoned entrepreneur with almost 30 years of fiscal, strategic and operational leadership. Mr. Sabi founded and led SABi Ventures and SABi Trading and Contracting, Inc., which focused on international trade, retail and real estate. Formerly, Mr. Sabi was CEO and/or Director of White House / Black Market, Inc. (acquired by Chico’s, Inc. in 2000), Roadhouse Grill, Inc. (IPO 1996 NASDAQ), New Global, LLC (shopping centers, sold 2002) and National Retail Group, Inc.
Mr. Sabi has a B.S. from North Carolina State University.







Wonpyo Yun
Analyst








Wonpyo Yun

Mr. Yun joined Aisling in July 2016 and serves as an Analyst. Previously, Mr. Yun was an Analyst in the Healthcare Investment Banking Group at Credit Suisse in New York.
Mr. Yun holds an A.B. in Molecular Biology, awarded magna cum laude, from Princeton University, where he also received a Certificate in Finance.







Robert J. Wenzel
Chief Financial Officer








Robert J. Wenzel

Mr. Wenzel joined Aisling in June 2008 and has served as Chief Financial Officer since April 2017, having previously served as Controller for nine years. For 12 years prior to joining Aisling, he was Vice President at Lazard Alternative Investments (“Lazard”) where he supervised the financial reporting of several domestic and offshore private equity funds. Prior to joining Lazard, Mr. Wenzel began his career at Eisner & Lubin, LLP, a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele, attaining the role of Senior Accountant.
Mr. Wenzel received his B.B.A. in Accounting from Baruch College in 1993 and holds his Certified Public Accountant license in the state of New York. He is also a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.







Hannah Wieder
Controller








Hannah Wieder

Ms. Wieder joined Aisling in March 2017 and serves as the Controller. Prior to joining Aisling, she was an audit manager in the wealth & asset management practice at Ernst & Young, where her focus was on private equity. Ms. Wieder also spent six years in the financial services group at CohnReznick, a midsize public accounting firm, where she attained the role of Audit Manager and directed the annual audits of various clients within the financial services industry including private equity funds, funds of funds and management companies.
Ms. Wieder received her M.S. in accountancy from the Zicklin School of Business at Baruch College and received her B.S. in business management and finance, awarded magna cum laude, from Brooklyn College. She is a Certified Public Accountant licensed in the State of New York and is a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.







Jan Hoerrner
Director of Investor Relations and Marketing








Jan Hoerrner

Ms. Hoerrner joined Aisling in October of 2000 and serves as the Director of Investor Relations and Marketing at Aisling Capital. In this role, Ms. Hoerrner manages relationships with over eighty limited partners, and is a key contributor in Aisling’s fundraising and marketing efforts. Previously, Ms. Hoerrner was with H&Q, a leading underwriter and strategic advisor to the biotechnology industry. During her five years at H&Q, Ms. Hoerrner was responsible for coordinating their Healthcare Conferences and also served as Administrative Manager for the New York office.
Ms. Hoerrner received her B.S. in Business Administration from Bryant University.


















About : Aisling Capital : Life Sciences Private Equity






























Toggle navigation










About


A DIFFERENTIATED APPROACH TO HEALTHCARE
Aisling Capital is a leading investment firm that invests in products,
technologies, and global businesses that advance health.
Since 2000, Aisling Capital has raised over $1.8 billion in committed capital across four funds. Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team’s combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry.





12investment professionals with a combined 150+ years of experience in the healthcare industry.
1.8billion dollars raised in committed capital across 4 funds with a track record of investing and returning capital since 2000.
96investments made to date, across development stage and capital structure, including both private and public companies.
 






Our Strategy
Aisling Capital seeks to identify differentiated healthcare products, services and technologies that address unmet medical needs. Our business is to provide promising companies with meaningful capital resources and to assist them in achieving their growth objectives. We identify healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance the opportunities for success.


Our Investments
Aisling Capital makes investment decisions driven by fundamental assessment of scientific, regulatory, financial and commercial risks. Given our investment team’s broad skillset, we invest across the life sciences, including seed and venture financings of development-stage companies, small-cap publicly traded equities, structured debt and royalty deals and large-cap leveraged buyouts of profitable companies.


Our Approach
Aisling Capital takes an active approach to investing, working closely with portfolio companies to help them become value-building enterprises with multiple opportunities for exit. Our investment professionals collaborate with management teams and contribute expertise and experience to help determine and execute strategy, identify and evaluate business opportunities and address financial issues.















Jan Hoerrner - Aisling Capital






























Toggle navigation










Team


Aisling Capital Team
Aisling Capital is led by a group of investment professionals with diverse backgrounds in
industry, science and finance.
The team’s complementary backgrounds give Aisling Capital unique perspective on the key players, events, and forces shaping the life science industry, and allow the Fund to identify investment opportunities. In working with our portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships, and guidance needed to build highly successful companies.










Steven A. Elms
Managing Partner








Steven A. Elms

Mr. Elms joined Aisling in July of 2000 and currently serves as one of the Managing Partners. Previously, he was a Principal in the Life Sciences Investment Banking Group of H&Q. During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.
Mr. Elms currently serves as a director of ADMA Biologics, EarLens and Loxo Oncology. Previously he served as a director of Advion BioSciences, Ambit Biosciences, Archimica Cooperatief, Avera Pharmaceuticals, Bioenvision, CeNeRx BioPharma, Cidara Therapeutics, LENSAR, NextWave Pharmaceuticals, Novazyme Pharmaceuticals, Pernix Therapeutics, Scerene Healthcare and TRIA Beauty and was Chairman of the Board of Adams Respiratory Therapeutics, MAP Pharmaceuticals and Oculex Pharmaceuticals.
Mr. Elms received his M.B.A. from the Kellogg Graduate School of Management at Northwestern University and his B.A. in Human Biology from Stanford University.







Andrew Schiff, MD
Managing Partner








Andrew Schiff, MD

Dr. Schiff joined Aisling in September of 1999 and currently serves as one of the Managing Partners. Prior to Aisling Capital, Dr. Schiff practiced internal medicine for six years at The New York Presbyterian Hospital, where he maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff currently serves as a director of ARMGO Pharma, PowerVision and ZELTIQ Aesthetics, and as a Board observer of Zavante Therapeutics. Prior Board service includes Adams Respiratory Therapeutics, Agile Therapeutics, ArgiNOx Pharmaceuticals, Barrier Therapeutics, Bioenvision, CardioKine, Cempra Pharmaceuticals, Miramar Labs, Myogen, SkinMedica, Sirion Therapeutics, TransEnterix and Quintiles (Board observer). He is a longtime supporter and Board member of the Visiting Nurse Service of New York.
Dr. Schiff received his M.D. from Cornell University Medical College, his M.B.A. from Columbia University, and his B.S. with honors in Neuroscience from Brown University.







Dov A. Goldstein, MD
Managing Partner








Dov A. Goldstein, MD

Dr. Goldstein joined Aisling in 2006 and currently serves as one of the Managing Partners. Prior to joining Aisling, Dr. Goldstein served as Executive Vice President and Chief Financial Officer of Vicuron Pharmaceuticals for five years, up until its acquisition by Pfizer. While at Vicuron Pharmaceuticals, he raised over $250 million in an IPO, PIPE, follow-on and block trade transactions. He led the valuation and finance due diligence for the merger with Biosearch Italia (Nuovo mercato: BIO.MI), the first U.S. and Italian public-to-public company merger. He also ran the investor relations and press relations efforts for the company. Prior to Vicuron, Dr. Goldstein was Director of Venture Analysis at Healthcare Ventures. He also completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.
Dr. Goldstein currently serves as a director of ADMA Biologics, Cempra Pharmaceuticals and Esperion Therapeutics. Previously, he served as a director of Durata Therapeutics (acquired by Actavis), Loxo Oncology (also served as Chief Financial Officer) and Topaz Pharmaceuticals (acquired by Sanofi) and on other private company Boards.
Dr. Goldstein received his M.D. from Yale School of Medicine. He received his M.B.A. from Columbia Business School and his B.S. with honors from Stanford University.







Dennis J. Purcell
Founder and Senior Advisor








Dennis J. Purcell

Mr. Purcell is the original Founder of Aisling Capital LLC and currently serves as a Senior Advisor to Aisling. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Mr. Purcell served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist, “H&Q”) for over five years. While at H&Q, he was directly involved with over two hundred completed transactions and supervised over $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Mr. Purcell was a Managing Director in the Healthcare Group at PaineWebber, Inc.
Mr. Purcell is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry.
Mr. Purcell has served as a director of Aton Pharma, Bridge Pharmaceuticals, Cengent Therapeutics, Dynova Laboratories, Paratek Pharmaceuticals, Valentis and Xanodyne Pharmaceuticals. He has served as a member of the Advisory Council at Harvard Medical School, the Board of Directors of the Biotechnology Industry Association, as well as the New York Biotechnology Association, the Irvington Institute and on the Board of L.E.K. Consulting. He currently sits on the board of Real Endpoints, Summus Global, Inc., Life Science Leader Magazine –Editorial Advisory Board, NY BIO Association and is a member of The University of Delaware Investment Visiting Committee Member.
Mr. Purcell received his M.B.A. from Harvard University and his B.S. in Accounting from the University of Delaware.







Eric Aguiar, MD
Partner








Eric Aguiar, MD

Dr. Aguiar joined Aisling in 2016. Prior to joining Aisling, Dr. Aguiar was a partner at Thomas, McNerney and Partners, a $600 million health care focused venture capital and growth equity fund, from 2007-2015. Dr. Aguiar was a Managing Director of HealthCare Ventures, a health care venture capital fund, from 2001-2007. He currently sits on the boards of Biohaven and Invitae Corporation.
His prior board seats have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc (acquired by Allergan), Vaxinate, Inc., Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). He was CEO of Genovo, Inc. (acquired by Targeted Genetics), a biopharmaceutical company that specialized in gene delivery and gene regulation. He was also executive director of TheraTech, Inc. (acquired by Watson Pharmaceuticals). He was a Vice President and Managing Director of Philadelphia Ventures from 1992 to 1997.
Dr. Aguiar is a member of the Board of Overseers of the Tufts School of Medicine and a member of the Council on Foreign Relations. He received his Medical Degree with honors from Harvard Medical School. He graduated with honors from Cornell University as a College Scholar. He was also a Luce Fellow and is a Chartered Financial Analyst.







Aftab R. Kherani, MD
Partner








Aftab R. Kherani, MD

Dr. Kherani joined Aisling in 2008 and currently serves as a Partner. Previously, Dr. Kherani was an Engagement Manager for two years at McKinsey & Company, where he was a member of the Pharmaceutical, Medical Product and Private Equity practices. Prior to McKinsey, Dr. Kherani was a Chief Resident in Surgery at Duke University Medical Center, where he completed his residency in general surgery. He also completed a two-year post-doctoral research fellowship investigating treatments for heart failure and arrhythmia at Columbia University, College of Physicians & Surgeons. While at Columbia, he additionally served as an organ procurement fellow as part of the cardiothoracic transplantation team of New York Presbyterian Hospital.
Dr. Kherani currently serves as a director of Spirox and TransEnterix and as a Board observer at ARMGO Pharma, EarLens, Loxo Oncology, Syros Pharmaceuticals and T2 Biosystems.
Dr. Kherani received his M.D. from Duke University School of Medicine, where he was a Howard Hughes Medical Institute Research Fellowship recipient. He also received his B.S. in Biology and A.B. in Economics from Duke, both magna cum laude, graduating Phi Beta Kappa.







Stacey D. Seltzer
Partner








Stacey D. Seltzer

Ms. Seltzer joined Aisling in 2008 and currently serves as a Partner. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. While in business development, Ms. Seltzer was involved in the structuring and negotiation of several deals with an aggregate value in the billions, ranging from in-licensing deals to broad development and commercialization alliances. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company.
Ms. Seltzer serves as a director of Aimmune Therapeutics, Miramar Labs and Promentis Pharmaceuticals, and as a Board observer of Prolacta Bioscience. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics (acquired by Actavis) and ZELTIQ Aesthetics. She also acted as the Aisling representative for its investment in PreCision Dermatology (acquired by Valeant) and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision.
Ms. Seltzer received her M.B.A. from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her M.S. and B.S. from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.







Josh Bilenker, MD
Operating Partner








Josh Bilenker, MD

Dr. Bilenker joined Aisling in 2006 and currently serves as an Operating Partner. He is President and Chief Executive Officer of Loxo Oncology, an Aisling Capital III portfolio company. Prior to Aisling, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the U.S. Food and Drug Administration for two years. While at the FDA, he conducted clinical reviews of IND-stage and licensed biologic oncology products. Prior to joining the FDA, Dr. Bilenker trained at the University of Pennsylvania in internal medicine and medical oncology, earning board certification in these specialties.
Dr. Bilenker currently serves as a director of Loxo Oncology and ViewRay. Previously he served as a director of LENSAR, Roka Bioscience and T2 Biosystems, and as a Board observer at Aragon Pharmaceuticals. He is also a Board Member of the NCCN Foundation and of BioEnterprise.
Dr. Bilenker received his M.D. from The Johns Hopkins School of Medicine. He received his A.B. from Princeton, awarded summa cum laude in English.







Scott Braunstein, MD
Operating Partner








Scott Braunstein, MD

Dr. Braunstein serves as an Operating Partner at Aisling Capital.  He is Senior Vice President, Strategy and Corporate Development at Pacira Pharmaceuticals.  Dr. Braunstein spent 12 years as a Healthcare Analyst and Portfolio Manager at J.P. Morgan Asset Management, where he invested in and conducted diligence on a wide variety of pharmaceutical products and product candidates. He reviewed pharmaceutical company strategies, business models and management teams, and provided stock recommendations for the J.P. Morgan Asset Equity Group.
Dr. Braunstein serves as a director of Esperion Therapeutics, STAT Medical and the Cornell Alumni Association for the College of Agriculture and Life Sciences.
Dr. Braunstein received his M.D. from the Albert Einstein College of Medicine and completed his residency in internal medicine at Cornell University-New York Hospital.  He received his B.S. from Cornell University.







Ayman Sabi
Operating Partner








Ayman Sabi

Mr. Sabi is an independent consultant serving as an Operating Partner at Aisling Capital. He is the founder of SABi Medical Group, B.V., and a seasoned entrepreneur with almost 30 years of fiscal, strategic and operational leadership. Mr. Sabi founded and led SABi Ventures and SABi Trading and Contracting, Inc., which focused on international trade, retail and real estate. Formerly, Mr. Sabi was CEO and/or Director of White House / Black Market, Inc. (acquired by Chico’s, Inc. in 2000), Roadhouse Grill, Inc. (IPO 1996 NASDAQ), New Global, LLC (shopping centers, sold 2002) and National Retail Group, Inc.
Mr. Sabi has a B.S. from North Carolina State University.







Wonpyo Yun
Analyst








Wonpyo Yun

Mr. Yun joined Aisling in July 2016 and serves as an Analyst. Previously, Mr. Yun was an Analyst in the Healthcare Investment Banking Group at Credit Suisse in New York.
Mr. Yun holds an A.B. in Molecular Biology, awarded magna cum laude, from Princeton University, where he also received a Certificate in Finance.







Robert J. Wenzel
Chief Financial Officer








Robert J. Wenzel

Mr. Wenzel joined Aisling in June 2008 and has served as Chief Financial Officer since April 2017, having previously served as Controller for nine years. For 12 years prior to joining Aisling, he was Vice President at Lazard Alternative Investments (“Lazard”) where he supervised the financial reporting of several domestic and offshore private equity funds. Prior to joining Lazard, Mr. Wenzel began his career at Eisner & Lubin, LLP, a midsize public accounting firm where he performed audits and prepared tax reports for a diverse clientele, attaining the role of Senior Accountant.
Mr. Wenzel received his B.B.A. in Accounting from Baruch College in 1993 and holds his Certified Public Accountant license in the state of New York. He is also a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.







Hannah Wieder
Controller








Hannah Wieder

Ms. Wieder joined Aisling in March 2017 and serves as the Controller. Prior to joining Aisling, she was an audit manager in the wealth & asset management practice at Ernst & Young, where her focus was on private equity. Ms. Wieder also spent six years in the financial services group at CohnReznick, a midsize public accounting firm, where she attained the role of Audit Manager and directed the annual audits of various clients within the financial services industry including private equity funds, funds of funds and management companies.
Ms. Wieder received her M.S. in accountancy from the Zicklin School of Business at Baruch College and received her B.S. in business management and finance, awarded magna cum laude, from Brooklyn College. She is a Certified Public Accountant licensed in the State of New York and is a member of the American Institute of Certified Public Accountants and the New York State Society of Certified Public Accountants.







Jan Hoerrner
Director of Investor Relations and Marketing








Jan Hoerrner

Ms. Hoerrner joined Aisling in October of 2000 and serves as the Director of Investor Relations and Marketing at Aisling Capital. In this role, Ms. Hoerrner manages relationships with over eighty limited partners, and is a key contributor in Aisling’s fundraising and marketing efforts. Previously, Ms. Hoerrner was with H&Q, a leading underwriter and strategic advisor to the biotechnology industry. During her five years at H&Q, Ms. Hoerrner was responsible for coordinating their Healthcare Conferences and also served as Administrative Manager for the New York office.
Ms. Hoerrner received her B.S. in Business Administration from Bryant University.


















Portfolio : Aisling Capital : Life Sciences Private Equity






























Toggle navigation










Portfolio


Aisling Capital invests in products, technologies and businesses that advance health.
In addition to investing in companies developing pharmaceutical, biotechnology and medical products, Aisling invests in businesses that provide drug development, manufacturing and other important services to the healthcare industry.




Portfolio Companies



AllSector

Biopharma
Consumer
Diagnostics
Medical Device
Services


Geographic Area

Ex-US
Mid-Atlantic
Midwest
Mountain
New England
South
West Coast


Status

CurrentHistoric
















Aclaris Therapeutics, Inc.
NasdaqGS: ACRS
Specialty pharmaceutical company, focusing on identifying, developing, and commercializing topical drugs to address various needs in dermatology.

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationMalvern, PA
Websiteaclaristx.com













Adams Respiratory Therapeutics, Inc.
Specialty pharmaceutical company engaged in the development, commercialization and marketing of over-the-counter and prescription drugs for the treatment of respiratory disorders

Year Invested2001
FundI
SectorConsumer
Company Statusacquired
Investment Statushistoric
LocationChester, NJ
Websiterb.com













ADMA Biologics, Inc.
NasdaqCM:ADMA
Biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics for the treatment and prevention of infectious diseases

Year Invested2007
FundII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationRamsey, NJ
Websiteadmabiologics.com













Advion, Inc.
Provider of bioanalytical testing equipment to the pharmaceutical industry

Year Invested2002
FundI
SectorServices
Company Statusprivate
Investment Statushistoric
LocationIthaca, NY
Websiteadvion.com













Agile Therapeutics, Inc.
NasdaqGM:AGRX
Women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products

Year Invested2012
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationPrinceton, NJ
Websiteagiletherapeutics.com













Aimmune Therapeutics, Inc.
NasdaqGS:AIMT
Biopharmaceutical company developing desensitization treatments for food allergies

Year Invested2015
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationBrisbane, CA
Websiteaimmune.com













Ajax Health
Medical device platform building a diversified portfolio of emerging medical device companies

Year Invested2017
FundIV
SectorMedical Device
Company Statusprivate
Investment Statuscurrent
LocationMenlo Park, CA
WebsiteNA













Allos Therapeutics, Inc.
Biopharmaceutical company engaged in the development and commercialization of anti-cancer therapeutics

Year Invested2002
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationWestminster, CO
Websitesppirx.com













Ambit Biosciences Corporation
Biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat oncology, autoimmune and inflammatory diseases

Year Invested2001
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationSan Diego, CA
Websiteambitbio.com













Aragon Pharmaceuticals, Inc.
Oncology drug development company focused on novel therapeutics for prostate and breast cancer

Year Invested2010
FundIII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationNew Brunswick, NJ
Websitejnj.com













Archimica Cooperatief U.A.
Manufacturer of active pharmaceutical ingredients and late state intermediates for the pharmaceutical industry

Year Invested2006
FundII
SectorServices
Company Statusacquired
Investment Statushistoric
LocationAmsterdam, Netherlands
Websiteeuticals.com













ARMGO Pharma, Inc.
Biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular and neurological disorders

Year Invested2006
FundII
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationTarrytown, NY
Websitearmgo.com













Ascendis Pharma A/S
NasdaqGS:ASND
Endocrine-focused biopharmaceutical company developing long-acting human growth hormone for the treatment of pediatric growth hormone deficiency

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationHellerup, Denmark
Websiteascendispharma.com













Aton Pharma, Inc.
Biotechnology company focused on the development of novel treatments for cancer

Year Invested2002
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationTarrytown, NY
Websitemerck.com













Audentes Therapeutics, Inc.
NasdaqGM:BOLD
Biotechnology company developing gene therapy-based treatments in several serious, rare diseases

Year Invested2017
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationSan Francisco, CA
Websiteaudentestx.com













Auxilium Pharmaceuticals, Inc.
NasdaqGS:AUXL
Specialty pharmaceutical company that develops and markets pharmaceutical products for urology and sexual health

Year Invested2003
FundI
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationChesterbrook, PA
Websiteauxilium.com













AVANZA Laboratories, LLC
Contract research organization that provides GLP complaint drug development services for biotechnology and pharmaceutical firms, and government agencies

Year Invested2009
FundII
SectorServices
Company Statusacquired
Investment Statushistoric
LocationGaithersburg, MD
Websitesmithersavanza.com













Axcan Pharma, Inc.
Specialty pharmaceutical company focused on the treatment of gastrointestinal disorders

Year Invested2000
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationQuebec, Canada
Websiteactavis.com













Barrier Therapeutics, Inc.
Specialty pharmaceutical company focused on development and commercialization of dermatology drugs

Year Invested2002
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationPrinceton, NJ
Websitestiefel.com













Bioenvision, Inc.
Biotechnology company focused on the development and commercialization of drugs to treat oncology and infectious disease

Year Invested2002
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationNew York, NY
Websitegenzyme.com













Biohaven Pharmaceuticals Ltd.
NYSE:BHVN
Biopharmaceutical company developing treatments for orphan neurologic indications and other areas of large unmet medical needs

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationNew Haven, CT
Websitebiohavenpharma.com













Cardiokine, Inc.
Biotechnology company developing drugs for the treatment and prevention of cardiovascular diseases

Year Invested2004
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationPhiladelphia, PA
Websitechiesiusa.com













Catalent, Inc.
NYSE:CTLT
Provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products

Year Invested2007
FundII
SectorServices
Company Statuspublic
Investment Statushistoric
LocationSomerset, NJ
Websitecatalent.com













Cempra, Inc.
NasdaqGS:CEMP
Drug discovery and development company focused on infectious diseases and the treatment of drug-resistant bacteria

Year Invested2006
FundII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationChapel Hill, NC
Websitecempra.com













Chimerix, Inc.
NasdaqGM:CMRX
Biopharmaceutical company dedicated to discovering, developing and commercializing novel, oral antivirals in areas of high unmet medical need

Year Invested2013
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationDurham, NC
Websitechimerix.com













Cidara Therapeutics, Inc.
NasdaqGM:CDTX
Drug discovery and development company focused on devastating fungal infections that often complicate cancer and transplant treatments

Year Invested2008
FundII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationSan Diego, CA
Websitecidara.com













Clovis Oncology, Inc.
NasdaqGS:CLVS
Biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents

Year Invested2011
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationBoulder, CO
Websiteclovisoncology.com













CollaGenex Pharmaceuticals, Inc.
Specialty pharmaceutical company that develops and markets proprietary medical therapies to the dermatology market

Year Invested2001
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationNewton, PA
Websitegalderma.com













Colorescience, Inc.
Cosmetics company that manufactures and sells mineral-based products

Year Invested2012
FundI
SectorConsumer
Company Statusacquired
Investment Statushistoric
LocationCarlsbad, CA
Websitecolorescience.com













Cynapsus Therapeutics Inc.
NasdaqGM:CYNA
Specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson’s disease

Year Invested2015
FundIII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationToronto, Canada
Websitecynapsus.ca













Cytos Biotechnology AG
SWX:CYTN
Biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform

Year Invested2012
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationSchlieren, Switzerland
Websitecytos.com













Dermira, Inc.
NasdaqGS:DERM
Specialty biopharmaceutical company focused on bringing innovative and differentiated medical dermatology products to dermatologists and their patients

Year Invested2014
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationRedwood City, CA
Websitedermira.com













Durata Therapeutics, Inc.
Pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and providers to advance patient care in infectious disease and acute illnesses

Year Invested2009
FundIII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationChicago, IL
Websiteduratatherapeutics.com













EarLens Corporation
Medical device company committed to providing hearing impaired patients a hearing solution that is designed to change the current standard of care for sound performance.

Year Invested2014
FundIII
SectorMedical Device
Company Statusprivate
Investment Statuscurrent
LocationMenlo Park, CA
Websiteearlenscorp.com













Esperion Therapeutics, Inc.
NasdaqGM:ESPR
Drug discovery and development company focused on therapies that prevent, treat and reverse cardiovascular and metabolic diseases

Year Invested2008
FundII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationAnn Arbor, MI
Websiteesperion.com













F2G Limited
Antifungal drug discovery and development company focused on novel therapies to treat life threatening invasive fungal infections

Year Invested2016
FundIV
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationManchester, UK
Websitef2g.com













Global Blood Therapeutics, Inc.
NasdaqGS:GBT
Biopharmaceutical company developing novel therapies to improve the lives of patients with serious blood-based disorders

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationSouth San Francisco, CA
Websiteglobalbloodtx.com













Ibrutinib Royalty
Anti-cancer drug targeting B-cell malignancies

Year Invested2013
FundIII
SectorBiopharma
Company Statusprivate
Investment Statushistoric
LocationN/A
Websiteimbruvica.com













Infinity Pharmaceuticals, Inc.
NasdaqGS:INFI
Biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to patients with difficult-to-treat diseases

Year Invested2012
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationCambridge, MA
Websiteinfi.com













Intercept Pharmaceuticals, Inc.
NasdaqGS:ICPT
Biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing our proprietary bile acid chemistry

Year Invested2012
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationNew York, NY
Websiteinterceptpharma.com













Intersect ENT, Inc.
NasdaqGM:XENT
Commercial stage drug-device company committed to improving the quality of life for patients with ear, nose and throat conditions

Year Invested2014
FundIII
SectorMedical Device
Company Statuspublic
Investment Statuscurrent
LocationMenlo Park, CA
Websitepropelopens.com













LENSAR, Inc.
Leader in next-generation femtosecond laser technology for refractive cataract surgery

Year Invested2008
FundII
SectorMedical Device
Company Statusprivate
Investment Statuscurrent
LocationOrlando, FL
Websitelensar.com













Lombard Medical, Inc.
NasdaqGM:EVAR
Medical technology company specializing in developing, manufacturing and marketing endovascular stent-grafts that address significant unmet needs in the repair of aortic aneurysms

Year Invested2014
FundIII
SectorMedical Device
Company Statuspublic
Investment Statushistoric
LocationOxfordshire, UK
Websitelombardmedical.com













Loxo Oncology, Inc.
NasdaqGM:LOXO
Biotechnology company developing targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations

Year Invested2013
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationStamford, CT
Websiteloxooncology.com













MAP Pharmaceuticals, Inc.
Specialty pharmaceutical company developing new therapies based on proprietary drug particle and inhalation technologies

Year Invested2003
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationMountain View, CA
Websiteallergan.com













MEI Pharma, Inc.
NasdaqCM:MEIP
Oncology company focused on the clinical development of novel therapies for cancer

Year Invested2013
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationSan Diego, CA
Websitemeipharma.com













Menlo Therapeutics Inc.
Biopharmaceutical company developing an oral therapy for the treatment of chronic pruritus associated with various conditions and chronic cough

Year Invested2017
FundIV
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationMenlo Park, CA
Websitemenlotherapeutics.com













Miramar Labs, Inc.
OTC:MRLB
Medical device company focused on developing products for dermatologic medical conditions

Year Invested2011
FundIII
SectorMedical Device
Company Statuspublic
Investment Statuscurrent
LocationSunnyvale, CA
Websitemiradry.com













Myogen, Inc.
Biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders

Year Invested2001
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationWestminster, CO
Websitegilead.com













NextWave Pharmaceuticals, Inc.
Specialty pharmaceutical company developing extended release OTC and prescription products for children and adults

Year Invested2007
FundII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationCupertino, CA
Websitepfizer.com













Novazyme Pharmaceuticals, Inc.
Biotechnology company focused on drugs to treat lysosomal storage diseases

Year Invested2000
FundI
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationPrinceton, NJ
Websitegenzyme.com













Oculex Pharmaceuticals, Inc.
Ophthalmic drug delivery company with platform technology to facilitate the treatment of major sight-threatening eye diseases and conditions

Year Invested2002
FundI
SectorMedical Device
Company Statusacquired
Investment Statushistoric
LocationSunnyvale, CA
Websiteallergan.com













Paratek Pharmaceuticals, Inc.
NasdaqGM:PRTK
Biopharmaceutical company engaged in the discovery, development and commercialization of antibiotics to save lives and alleviate suffering

Year Invested2007
FundII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationBoston, MA
Websiteparatekpharm.com













Pernix Therapeutics, Inc.
NasdaqGM:PTX
Specialty pharmaceutical company primarily focused on the sales, marketing and development of branded pharmaceutical products

Year Invested2011
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationHouston, TX
Websitepernixtx.com













Pharmaron, Inc.
Provider of research and development services for pharmaceutical and biotechnological industries worldwide

Year Invested2006
FundII
SectorServices
Company Statusprivate
Investment Statushistoric
LocationBeijing, China
Websitepharmaron.com













Planet Biopharmaceuticals, Inc.
Developer and manufacturer of allergenic extracts and other products for the treatment and prevention of allergy

Year Invested2007
FundII
SectorConsumer
Company Statusacquired
Investment Statushistoric
LocationLiberty, MO
Websiteareslifesciences.com













PowerVision, Inc.
Developer of a fluid-controlled intraocular lens

Year Invested2014
FundIII
SectorMedical Device
Company Statusprivate
Investment Statuscurrent
LocationBelmont, CA
Websitepowevisionlens.com













PreCision Dermatology, Inc.
Specialty pharmaceutical company developing, manufacturing and marketing prescription and consumer dermatology products

Year Invested2012
FundIII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationCumberland, RI
Websitevaleant.com













Prolacta Bioscience, Inc.
Biopharmaceutical company developing and marketing human milk-based nutritional products for premature infants in the neonatal intensive care unit

Year Invested2016
FundIV
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationCity of Industry, CA
Websiteprolacta.com













Promentis Pharmaceuticals, Inc.
Biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders of System XC-

Year Invested2016
FundIV
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationMilwaukee, WI
Websitepromentispharma.com













Protagonist Therapeutics, Inc.
NasdaqGM: PTGX
Clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based new chemical entities to address significant unmet medical needs in inflammatory bowel diseases

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationMilpitas, CA
Websiteprotagonist-inc.com













Quintiles Transnational Holdings Inc.
NYSE:Q
Contract pharmaceutical research and sales organization

Year Invested2003
FundI
SectorServices
Company Statuspublic
Investment Statushistoric
LocationDurham, NC
Websitequintiles.com













Roka Bioscience, Inc.
NasdaqGM:ROKA
Molecular diagnostics company focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens

Year Invested2011
FundIII
SectorDiagnostics
Company Statuspublic
Investment Statushistoric
LocationWarren, NJ
Websiterokabio.com













Seragon Pharmaceuticals, Inc.
Biopharmaceutical company focused on developing drugs for the treatment of estrogen receptor dependent breast cancer

Year Invested2013
FundIII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationSan Diego, CA
Websitegene.com













Sirion Therapeutics, Inc.
Ophthalmic-focused biopharmaceutical company engaged in the discovery, development and commercialization of products for the protection and preservation of eyesight

Year Invested2007
FundII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationTampa, FL
WebsiteN/A













SkinMedica, Inc.
Specialty pharmaceutical company focused on development and commercialization of dermatology drugs and cosmeceuticals

Year Invested2004
FundI
SectorConsumer
Company Statusacquired
Investment Statushistoric
LocationCarlsbad, CA
Websiteskinmedica.com













Sorrento Therapeutics, Inc.
NasdaqCM:SRNE
Biopharmaceutical company engaged in the discovery, acquisition, development and commercialization of proprietary drug therapeutics for addressing significant unmet medical needs

Year Invested2013
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationSan Diego, CA
Websitesorrentotherapeutics.com













Spirox, Inc.
Medical device company that is focused on developing minimally invasive technologies that improve the quality of life for patients with nasal obstruction

Year Invested2015
FundIII
SectorMedical Device
Company Statusacquired
Investment Statushistoric
LocationMenlo Park, CA
Websitespiroxmed.com













Sunesis Pharmaceuticals, Inc.
NasdaqCM:SNSS
Biopharmaceutical company developing oncology therapeutics for the treatment of solid and hematologic cancers

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationSan Francisco, CA
Websitesunesis.com













Synergy Pharmaceuticals Inc.
NasdaqGS:SGYP
Biopharmaceutical company focused on the development of novel therapies based on the natural human hormone, uroguanylin, to treat gastrointestinal (GI) diseases and disorders

Year Invested2014
FundIII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationNew York, NY
Websitesynergypharma.com













Syros Pharmaceuticals, Inc.
NasdaqGS:SYRS
Life sciences company harnessing breakthroughs in gene control to revolutionize the treatment of cancer and other diseases

Year Invested2014
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationWatertown, MA
Websitesyros.com













T2 Biosystems, Inc.
NasdaqGM:TTOO
In vitro diagnostics company that has developed a technology platform that offers a rapid, sensitive and simple alternative to existing diagnostic methodologies

Year Invested2011
FundIII
SectorDiagnostics
Company Statuspublic
Investment Statuscurrent
LocationLexington, MA
Websitet2biosystems.com













Topaz Pharmaceuticals, Inc.
Specialty pharmaceutical company focused on developing and commercializing treatments primarily for the pediatric and dermatology markets.

Year Invested2007
FundII
SectorBiopharma
Company Statusacquired
Investment Statushistoric
LocationHorsham, PA
Websitesanofi.us













TransEnterix, Inc.
NYSEMKT:TRXC
Medical device company that is focused on the development and commercialization of manual and robotic assisted surgical systems for minimally invasive surgery

Year Invested2009
FundIII
SectorMedical Device
Company Statuspublic
Investment Statuscurrent
LocationMorrisville, NC
Websitetransenterix.com













TRIA Beauty, Inc.
Medical device company developing and commercializing at-home, light-based skincare products

Year Invested2008
FundII
SectorConsumer
Company Statusprivate
Investment Statuscurrent
LocationDublin, CA
Websitetriabeauty.com













Verona Pharma plc
NasdaqGM:VRNA
UK-based biopharmaceutical company focused on the development of innovative prescription medicines to treat respiratory diseases with significant medical unmet needs

Year Invested2016
FundIV
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationLondon, UK
Websiteveronapharma.com













Versartis, Inc.
NasdaqGS:VSAR
Endocrine-focused biopharmaceutical company developing novel long-acting recombinant human growth hormone for growth hormone deficiency

Year Invested2013
FundIII
SectorBiopharma
Company Statuspublic
Investment Statuscurrent
LocationRedwood City, CA
Websiteversartis.com













ViewRay, Inc.
OTCQB: VRAY
Medical device company developing advanced radiation therapy technology for the treatment of cancer

Year Invested2008
FundII
SectorMedical Device
Company Statuspublic
Investment Statuscurrent
LocationOakwood Village, OH
Websiteviewray.com













VIVUS, Inc.
NasdaqGS:VVUS
Biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes, sleep apnea and sexual health

Year Invested2006
FundII
SectorBiopharma
Company Statuspublic
Investment Statushistoric
LocationMountain View, CA
Websitevivus.com













Zavante Therapeutics, Inc.
Biopharmaceutical company focused on novel products that address serious unmet medical needs in the hospital

Year Invested2016
FundIV
SectorBiopharma
Company Statusprivate
Investment Statuscurrent
LocationSan Diego
Websitezavante.com













ZELTIQ Aesthetics, Inc.
NasdaqGS:ZLTQ
Medical technology company focused on developing and commercializing products utilizing a controlled cooling technology platform for non-invasive fat reduction

Year Invested2010
FundIII
SectorConsumer
Company Statusacquired
Investment Statushistoric
LocationPleasanton, CA
Websitecoolsculpting.com
















AISLING CAPITAL III LP - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











AISLING CAPITAL III LP
Check out list of companies and businesses related to AISLING CAPITAL III LP. Find out AISLING CAPITAL III LP address and contact details. View other people related to AISLING CAPITAL III LP - coworkers, colleagues, companions, etc.
Address:   

888 SEVENTH AVENUE 30TH FL NEW YORK 10106 NY




Companies related to AISLING CAPITAL III LP
CIKCompany NamePositionCompany Address0000876378TRANSENTERIX INC.10% Owner 635 DAVIS DRIVE SUITE 300 MORRISVILLE 275600001261249AGILE THERAPEUTICS INC101 POOR FARM ROAD  PRINCETON 08540-17150001544116Durata Therapeutics, Inc.10% Owner 200 SOUTH WACKER DRIVE SUITE 2550 CHICAGO 60606




AISLING CAPITAL III LP on the Web
Persons related to AISLING CAPITAL III LP - TRANSENTERIX INC.NamePositionCityJackson  AdamMiamiKherani, M.D.  AftabMiamiKherani  AftabMorrisvilleAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LPNEW YORKAisling Capital Partners III LPNEW YORKAisling Capital Partners III LPNEW YORKBiffi  AndreaMorrisvilleJOSHUA J  ANGELDirector SEATTLEJOSHUA J  ANGELDirector NEW YORKFernando  AnthonyMorrisvilleBARRY J  BEILDirector SEATTLEAndrea  BiffiDirector TREZZANO ROSAKenneth  BlockChief Financial Officer VALLEY STREAMChen  ChaoMiamiChen  ChaoMiamiFilipi  CharlesMiamiFilipi  CharlesMiamiFilipi, M.D.  CharlesMiamiChao C  ChenTAIPEIChao C  ChenDirector MIAMIMilne  DavidMiamiMilne  DavidMorrisvilleStewart B  DavisCOO & Secretary MIAMIStewart B  DavisCOO MIAMIStewart B  DavisCOO MIAMIDougherty  DennisMiamiDennis  DoughertyDirector DURHAMDennis  DoughertyDirector DURHAMSTEVE  ELMSCHESTERSTEVE  ELMSNEW YORKSTEVE  ELMSNEW YORKSTEVE  ELMSNEW YORKAnthony C. J.  FernandoChief Operating Officer MORRISVILLECharles  FilipiOMAHACharles  FilipiDirector MIAMICharles  FilipiChief Medical Officer MIAMIFrost Gamma Investment TrustMIAMIFrost Gamma Investment TrustMIAMIFrost Gamma Investment TrustMIAMIFrost Gamma Investment TrustMIAMIFrost Gamma Investments TrustMIAMIFrost Gamma Investments TrustMIAMIFrost Gamma Investments TrustMIAMIFrost Gamma Investments TrustMIAMIPHILLIP MD ET AL  FROST10% Owner MIAMIPHILLIP MD ET AL  FROST10% Owner MIAMIPHILLIP MD ET AL  FROST10% Owner MIAMIPHILLIP MD ET AL  FROSTMIAMIKenneth  HeithoffDirector MINNEAPOLISKenneth  HeithoffDirector FISHER ISLANDJANE PH D  HSIAODirector JANE PH D  HSIAODirector MIAMIJANE PH D  HSIAODirector MIAMIJANE PH D  HSIAOMIAMIJANE PH D  HSIAODirector MIAMIAdam S  JacksonMIAMIAdam S  JacksonCFO MIAMIAdam S  JacksonChief Financial Officer MIAMIMudit K.  JainPORTOLA VALLEYMartin  JamesMiamiMartin  JamesMiamiMartin  JamesMiamiHsiao  JaneMiamiHsiao  JaneMiamiHsiao  JaneMorrisvilleHsiao, Ph.D.  JaneMiamiSpragens  JeffreyMiamiSpragens  JeffreyMiamiSlattery  JosephMorrisvilleSTEPHEN  KATZChief Executive Officer SEATTLESTEPHEN  KATZChief Executive Officer VALLEY STREAMWILLAM N  KELLEYDirector WILLAM N  KELLEYDirector MORRISVILLEWayne  KevinMiamiWayne  KevinMiamiAftab  KheraniDirector NEW YORKPAUL A  LAVIOLETTEDirector NATICKPAUL A  LAVIOLETTEDirector BOSTONJames Joseph  MartinChief Financial Officer MIAMIDavid Bruce  MilneDirector BOSTONDavid Bruce  Milne10% Owner BOSTONRichard  MuellerMIAMIRichard  MuellerChief Operating Officer MORRISVILLELaViolette  PaulMiamiLaViolette  PaulMorrisvilleRICHARD C  PFENNIGER JRDirector MIAMIRICHARD C  PFENNIGER JRDirector MIAMIRICHARD C  PFENNIGER JRDirector MIAMIRICHARD C  PFENNIGER JRDirector MORRISVILLERICHARD C  PFENNIGER JRMIAMIRICHARD C  PFENNIGER JRDirector MIAMIFrost, M.D.  PhillipMiamiTodd  PopePresident and CEO MIAMITodd  PopePresident and CEO MORRISVILLEDennis J  PurcellNEW YORKDennis J  PurcellNEW YORKDennis J  PurcellNEW YORKPfenniger, Jr.  RichardMiamiPfenniger, Jr.  RichardMiamiPfenniger, Jr.  RichardMiamiJr.  Pfenniger  Richard,MorrisvilleMueller  RichardMiamiSteven D  RubinDirector MIAMISteven D  RubinDirector MIAMISteven D  RubinMIAMISteven D  RubinDirector MIAMIANDREW N  SCHIFFNEW YORKANDREW N  SCHIFFNEW YORKDR DREW  SCHIFFNEW YORKLAWRENCE  SCHOENBERGDirector SEATTLEJOSEPH P  SLATTERYEVP and CFO JOSEPH P  SLATTERYEVP and CFO MORRISVILLES.p.A  SOFAR,10% Owner TREZZANO ROSAJeffrey G  SpragensPresident and CEO MIAMIJeffrey G  SpragensPresident and CEO MIAMIJeffrey G  SpragensPresident and CEO MIAMIJeffrey G  SpragensCEO MIAMIJeffrey G  SpragensPresident and CEO MIAMIJeffrey G  SpragensPresident and CEO MIAMIRichard S.  Stack10% Owner PORTOLA VALLEYWilliam N  Starling JRDirector POCATELLOWilliam N  Starling JRDirector PORTOLA VALLEYWilliam N  Starling JRDirector PORTOLA VALLEYStepStone Group Holdings LLC10% Owner NEW YORKStepStone Group Holdings LLCNEW YORKStepStone Group LPSAN DIEGOStepStone PC GP, LLCNEW YORKStepStone PC GP, LLCNEW YORKStepStone Pioneer Capital Buyout Fund II, L.P.NEW YORKStepStone Pioneer Capital Buyout Fund II, L.P.NEW YORKStepStone Pioneer Capital II, L.P.NEW YORKStepStone Pioneer Capital II, L.P.505 FIFTH AVE., 17TH FLOORInvestments, L.L.L.P.  StepStone-SYNNEW YORKInvestments, L.L.L.P.  StepStone-SYNNEW YORKRubin  StevenMiamiRubin  StevenMiamiDavis  StewartMiamiSV Life Sciences Fund IV (GP), L.P.BOSTONSV LIFE SCIENCES FUND IV, L.P.BOSTONSV LIFE SCIENCES FUND IV STRATEGIC PARTNERS, L. P.BOSTONSVLSF IV, LLC10% Owner BOSTONSYNERGY LIFE SCIENCE PARTNERS L P10% Owner PORTOLA VALLEYSynergy Venture Partners, LLCPORTOLA VALLEYPope  ToddMiamiPope  ToddMorrisvilleUniMed Investment Inc.TAIPEIKevin  WayneDirector MIAMIKevin  WayneDirector MIAMIKevin  WayneDirector MIAMIKevin  WayneDirector MIAMIJr.  Starling  William,MorrisvilleKelley  WilliamMorrisvilleStarling, Jr.  WilliamMiamiPersons related to AISLING CAPITAL III LP - AGILE THERAPEUTICS INCNamePositionCityLele  AbhijeetNew YorkLeLe  AbhijeetNew YorkLele  AbhijeetPrincetonAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LPNEW YORKAisling Capital Partners III LPNEW YORKAisling Capital Partners III LPNEW YORKAltomari  AlLawrencevilleAltomari  AlPrincetonAltomari  AlPrincetonAltomari  AlPrincetonALFRED  ALTOMARIChairman and Chief Executive O PRINCETONALFRED  ALTOMARIChief Executive Officer PRINCETONSchiff  AndrewPrincetonSchiff  AndrewNew YorkCare Capital III LLC10% Owner PRINCETONCare Capital Investments III L.P.PRINCETONCare Capital Offshore Investments III LPPRINCETONScott M  CoianteChief Financial Officer PRINCETONBlackwell  DariaMahwahMiller  DeanWayneKantesaria  DevangWayneGarner  ElizabethPrincetonSTEVE  ELMSCHESTERSTEVE  ELMSNEW YORKSTEVE  ELMSNEW YORKSeth H.Z.  FischerDirector SAN DIEGOElizabeth  GarnerSr. VP & Chief Medical Officer PRINCETONGeoffrey  GilmoreGeneral Counsel CRANBURYKaren  HongDirector PRINCETONJohn W  HubbardDirector PRINCETONAB  INVESTOR10% Owner NEW YORKTursi  JamesPrincetonHubbard  JohnPrincetonTsang  JoycePrincetonHong  KarenPrincetonHong  KarenPrincetonHong  KarenPrincetonMacFarlane  KatiePrincetonAbhijeet J  LeleDirector WEST BERLINAbhijeet J  LeleDirector PRINCETONPellegrini  LorenzoPrincetonPellegrini  LorenzoPrincetonKatie  MacFarlaneChief Commercial Officer PRINCETONWILLIAM  MCKEEDirector WOODCLIFF LAKEWILLIAM  MCKEEPRINCETONJAY  MOORIN10% Owner SUITE 204Jay  Moorin10% Owner NAPLESSchmitt  PaulWayneProQuest Associates III LLCPRINCETON,ProQuest Associates III LLCNAPLESProQuest Associates IV LLCPRINCETONProQuest Associates IV LLCNAPLESProQuest Investments III, L.P.PRINCETON,ProQuest Investments III, L.P.NAPLESProQuest Investments IV, L.P.PRINCETONProQuest Investments IV, L.P.NAPLESDennis J  PurcellNEW YORKDennis J  PurcellNEW YORKDennis J  PurcellNEW YORKAyres  RussellPittsburghANDREW N  SCHIFFDirector NEW YORKANDREW N  SCHIFFDirector NEW YORKANDREW N  SCHIFFNEW YORKDR DREW  SCHIFFDirector NEW YORKALAIN  SCHREIBERPRINCETONALAIN  SCHREIBERNAPLESCoiante  ScottPrincetonCoiante  ScottPrincetonCoiante  ScottPrincetonRenee  SelmanChief Commercial Officer PRINCETONAjit  ShettyDirector PRINCETONRossi  ThomasPrincetonJames Patrick  TursiDirector MALVERNJames Patrick  TursiDirector PRINCETONMcKee  WilliamPrincetonPersons related to AISLING CAPITAL III LP - Durata Therapeutics, Inc.NamePositionCityBrenton Karl  AhrensDirector WESTPORTBrenton Karl  AhrensDirector WESTPORTAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LLCNEW YORKAisling Capital Partners III LPNEW YORKAisling Capital Partners III LPNEW YORKSRINIVAS  AKKARAJUMENLO PARKSRINIVAS  AKKARAJUMENLO PARKSusan Roberta  AllenMORRISTOWNAngela Gurski  BirchlerMORRISTOWNJAMES C  BLAIR10% Owner PRINCETONEric  BuatoisMENLO PARKCanaan Management, Inc.WESTPORTCanaan Management, Inc.WESTPORTCanaan Partners VIII LLCWESTPORTCanaan Partners VIII LLCWESTPORTCanaan VIII LPDirector WESTPORTCanaan VIII LPDirector WESTPORTJ MARTIN  CARROLLDirector CHICAGOJ MARTIN  CARROLLDirector CHICAGOPhilippe O.  ChambonNEW YORKPhilippe O.  ChambonNEW YORKPhilippe O.  ChambonNEW YORKSCHUTTER RICHARD U  DEDirector CHICAGOSCHUTTER RICHARD U  DEMORRISTOWNSCHUTTER RICHARD U  DEDirector CHICAGOSCHUTTER RICHARD U  DEDirector CHICAGOJeani  DelagardelleMENLO PARKJeani  DelagardelleMENLO PARKJeani  DelagardelleNEW YORKASSOCIATES  DOMAIN10% Owner PRINCETONDomain Partners VIII, L.P.10% Owner PRINCETONBRIAN H  DOVEY10% Owner PRINCETONDP VIII Associates, L.P.10% Owner PRINCETONMichael W.  DunneChief Medical Officer MORRISTOWNMichael W.  DunneChief Medical Officer CHICAGOMichael W.  DunneChief Medical Officer CHICAGOPaul R  EdickChief Executive Officer MORRISTOWNPaul R  EdickChief Executive Officer CHICAGOPaul R  EdickChief Executive Officer CHICAGOSTEVE  ELMSNEW YORKSTEVE  ELMSNEW YORKCorey N.  FishmanCOO & CFO MORRISTOWNCorey N.  FishmanCFO & COO CHICAGOCorey N.  FishmanCFO&COO CHICAGOPAUL A  FRIEDMANDirector CHICAGOPAUL A  FRIEDMANDirector CHICAGOLisa M.  GilesDirector CHICAGOLisa M.  GilesCHICAGOLisa M.  GilesDirector CHICAGODOV A MD  GOLDSTEINDirector NEW YORKBrian K  Halak10% Owner PRINCETONJAMES  HEALYDirector MENLO PARKJAMES  HEALYMENLO PARKGEORGE F  HORNER IIIDirector MORRISTOWNRONALD  HUNTNEW YORKRONALD  HUNTDirector NEW YORKRONALD  HUNTNEW YORKKim P.  KamdarPRINCETONMilan  KovacevicMORRISTOWNJeremy David  LackMORRISTOWNVijay K  LathiMENLO PARKVijay K  LathiMENLO PARKVijay K  LathiNEW YORKNew Leaf Venture Associates II, L.P.NEW YORKNew Leaf Venture Associates II, L.P.NEW YORKNew Leaf Venture Associates II, L.P.NEW YORKNew Leaf Venture Management II, L.L.C.NEW YORKNew Leaf Venture Management II, L.L.C.NEW YORKNew Leaf Venture Management II, L.L.C.NEW YORKNew Leaf Ventures II, L.P.NEW YORKNew Leaf Ventures II, L.P.10% Owner NEW YORKJAMES  NIEDELNEW YORKJAMES  NIEDELNEW YORKKEVIN C  OBOYLEDirector CHICAGOKEVIN C  OBOYLEDirector CHICAGOKEVIN C  OBOYLEMORRISTOWNBenjamin Manlaui  PeMORRISTOWNBenjamin Manlavi  PeCHICAGOMICHAEL  POWELLMENLO PARKDennis J  PurcellNEW YORKDennis J  PurcellNEW YORKLiam  RatcliffeNEW YORKANDREW N  SCHIFFNEW YORKANDREW N  SCHIFFNEW YORKKATHLEEN K  SCHOEMAKER10% Owner PRINCETONJohn Patrick  Shannon JrMORRISTOWNJohn Patrick  Shannon JrChief Commercial Officer CHICAGOJohn Patrick  Shannon JrChief Commercial Officer CHICAGOSofinnova Management VII, L.L.C.MENLO PARKSOFINNOVA VENTURE PARTNERS VII L PMENLO PARKGeorge Harrison  TalbotMORRISTOWNJESSE I  TREU10% Owner PRINCETONRonald Irving  TrustMORRISTOWNRonald Irving  TrustCHICAGONICOLE  VITULLODirector PRINCETONWENDY L  YARNOCHICAGOWENDY L  YARNODirector CHICAGO
Potentially same personNameCityCountryAISLING CAPITAL III LPNEW YORKNYAISLING CAPITAL III LPNEW YORKNYAISLING CAPITAL III LPNEW YORKNYAISLING CAPITAL III LPNEW YORKNYAISLING CAPITAL III LPNEW YORK,NY












 








Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version












﻿







Insider Aisling Capital Iii Lp Purchased $7.02 million of Loxo Oncology Inc (NASDAQ:LOXO) – Octafinance
























































 








Tuesday, 25 July 2017

























 

Menu



Featured News


						2 years ago - Alphabet Inc (NASDAQ:GOOGL) Tests Its Ad Technology On Billboards To Cushion Itself Against Ad Blocks


						2 years ago - China Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking Crisis


						2 years ago - Marc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and Gold


						2 years ago - Carl Icahn Criticizes the Fed. Feels Bad For Investors Buying Junk Bonds


						2 years ago - John Burbank: European QE Can’t Save The Markets Same As the U.S. Quantitative Easing. Everything Will Be Liquidated










Insider Aisling Capital Iii Lp Purchased $7.02 million of Loxo Oncology Inc (NASDAQ:LOXO)


11/22/2015  by OctaStaff 
			in Insider Buys $2m+, Insider Buys 10%+ Owner, Insider News 












Share with your friendsYour NameYour EmailRecipient EmailEnter a MessageI read this article and found it very interesting, thought it might be interesting for you. The article is called Insider Aisling Capital Iii Lp Purchased $7.02 million of Loxo Oncology Inc (NASDAQ:LOXO) and is was published by Octafinance.com at http://www.octafinance.com/insider-aisling-capital-iii-lp-purchased-7-02-million-of-loxo-oncology-inc-nasdaqloxo/291638/.CaptchaSubmit
Aisling Capital Iii Lp Insider Buy Transaction
 Aisling Capital Iii Lp, known as an insider in Loxo Oncology Inc (NASDAQ:LOXO)  72.98 -1.29 -1.74%, acquired 265,000 shares whose value is estimated to be $7.02 million at average stock price of $26.5. Being a significant transaction, it will probably not go ignored. Aisling Capital Iii Lp presently has rights to 22.45 % of Loxo Oncology Inc’s market cap with ownership of 3.80 million shares.  Dated 19-11-2015 the transaction filing is free at your disposal here.
Loxo Oncology Inc Stock Rating, Sentiment and Fundamentals
 Aisling Capital Iii Lp’s investment could mean only one: that it’s confident when it comes to Loxo Oncology Inc’s prospects and its stock price. According to four leading equity analysts that are covering this firm’s earnings potential, there is an expectation of per share earnings of $-1.96 for the 2015 year, which gives Loxo Oncology Inc a price to earnings ratio of NaN. 






Rating & SentimentPsychSignal Social:SELLAnalysts Rating:BUYHedge Funds Sentiment:BUY




Stock FundamentalsEarnings + FCF Trend:SELLSector/Industry Macro:BULLISHValuation Models:-


 


Technical AnalysisST Trend:UPMT Trend:UPLT Trend:UP




OctaFinance Rating*:BUY


* Read How Our Stock Ratings System Works








 We rate Loxo Oncology Inc’s stock as buy not only because of the insider transaction by Aisling Capital Iii Lp but also in accordance with OctaFinance’s sophisticated equities time momentum model as shown below. In the last 200 days, the Loxo Oncology Inc’s share price has seen a fast increase of 155.45 % and is now in a very smooth bullish uptrend. 
Price Chart of Loxo Oncology NASDAQ:LOXO Stock
 
Source: RightEdgeSystems, Yahoo Split & Dividend Adjusted Data and OctaFinance Interpretations
 Based on our analysis and trend model, Aisling Capital Iii Lp’s shareholders equity should advance by a total of $11.80 million USD should the stock price reaches our trading model target of $34.20. Please share with us if you buy the stock of Loxo Oncology Inc by commenting below.
Hedge Funds Ownership
 Latest 13F SEC filings show 48 investment managers own shares in Loxo Oncology Inc. The institutional ownership of the company in the last quarter is low, at 86.55 % of the shares outstanding. They increased by 1.06 million the total shares they hold. As of that quarter these funds owned 14.44 million shares. A total of 8 funds opened new positions in Loxo Oncology Inc and 28 increased their holdings. There were 6 funds that closed their positions and 7 that reduced them. 
 As revealed by SEC’s 13F filings, this company is in Top 10 stock holdings of two [HF3951]. Some of these are: Aisling Capital Llc, Bvf Inc Il.

 Dennis Purcell’s Aisling Capital Llc is the most positive institutional investor on Loxo Oncology Inc, with ownership of 3.45 million shares as of Q2 2015 for 9.27% of the fund’s portfolio. Bvf Inc Il is another positive institutional manager owning 1.62 million shares of the company or 5.14% of their stocks portfolio. The stock is also 2.91% of the fund’s AUM. Nea Management Company Llc have 1.69% of their stock portfolio invested in the company for 1.79 million shares. In addition, James E. Flynn’s Deerfield Management Co disclosed it had purchased a stake worth 0.87% of the fund’s stock portfolio in the company. The New York-based fund Orbimed Advisors Llc was also a notable believer in the -listed company, with ownership of 2.18 million shares. Loxo Oncology Inc is 0.33% of the fund’s stock portfolio.
Loxo Oncology NASDAQ:LOXO Company Profile
Loxo Oncology, Inc. is engaged in discovery, development, and commercialization of targeted cancer therapies. LOXO-101 is the Company’s lead product and has completed its pre-clinical research. LOXO-101 is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family. The Company is developing it for the treatment of tumors with TRK alterations. TRK has been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. The Company is conducting Phase 1 clinical trial of LOXO-101, which is an open label, multicenter trial and has two stages: dose escalation and expansion. The objectives of the dose escalation stage are to determine the tolerated dose and the appropriate dose for further clinical investigation, as well as to determine the tolerability and pharmacokinetic profile of orally administered LOXO-101.
Company Website: Loxo Oncology
 Currently its market worth is: $525.64 million and it has 16.91 million outstanding shares. As of writing there are 92.36% shareholders and the institutional ownership is 92.36%. The firm has 15 employees. Loxo Oncology Inc was created in Delaware on 2013-05-09. The stock closed at $30.91 yesterday and it had average 2 days volume of 49420 shares. It is up from the 30 days average shares volume of 42271. Loxo Oncology Inc has a one year low of $9.90 and a 250 days high of $32.30. The stock price is above the 200 days SMA. Loxo Oncology Inc last issued its quarterly earnings information on 11/10/2015. The company reported -0.53 EPS for the quarter, missing the consensus estimate of -0.52 by -0.01. The company had a revenue of for 9/30/2015 and for 6/30/2015. Therefore, the revenue was down.
Aisling Capital Iii Lp is also director of Agile Therapeutics Inc, 10 percent owner of Versartis, Inc., T2 Biosystems, Inc., Durata Therapeutics, Inc., Transenterix Inc., Zeltiq Aesthetics Inc.
* The securities are directly held by Aisling Capital III – LP (“Aisling”) – and indirectly held by Aisling Capital Partners III – LP (“Aisling GP”) – as general partner of Aisling – Aisling Capital Partners III LLC (“Aisling Partners”) – as general partner of Aisling GP – and each of the individual managing members and partners (collectively – the “Managers”) of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dennis Purcell – Dr. Andrew Schiff and Steve Elms. Mr. Elms is a member of the Issuer’s Board of Directors. Dr. Joshua Bilenker – the Issuer’s President and Chief Executive Officer – is a member of the Issuer’s Board of Directors and an Operating Partner of Aisling GP. Mr. Elms is a member of the investment committee (the “Investment Committee”) of Aisling GP. The Investment Committee has voting and dispositive power over the shares held by Aisling.

Loxo Oncology - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.



 



 
Tagged: Aisling Capital Iii LpLoxo Oncology - (NASDAQ:LOXO)



The director of Patrick Industries, Inc. (NASDAQ:PATK), Scott Welch Picked up 9,800 Shares Marubeni Corp /Fi, Insider in Aircastle Limited (NYSE:AYR), Paid for 15360 shares of the Company 



 





Loxo Oncology - Get News & Ratings Daily
    Enter your email address below to get the latest news and analysts' ratings for Loxo Oncology with our FREE daily email newsletter:



 



Hedge Fund NewsTop 10 CITADEL ADVISORS 13F Holdings in Q3 2015DF DENT & CO INC Just Released Its Q3 2015 Stock PositionsMAVERICK CAPITAL Top 10 Holdings in Q3 2015Analyzing Ken Griffins CITADEL ADVISORS Stock Holdings in Q3 2015LONE PINE CAPITAL Top 10 13F Positions in Q3 2015Guru NewsFelix Zulauf Sees a Stock Market Correction Coming. This Rally S&P 500 (INDEXSP:.INX) Will Be Short-LivedMarc Faber Shares His Insight in One Hour Exclusive Interview. He Covers All From Commodities and China to Inflation, The Euro and GoldJim Grant: The Next Thing Might Be Helicopter Money. What to Buy and Where He Sees Investment OpportunitiesKyle Bass Bearish on Emerging Markets for at least 2 More Years. Looking to Short CurrenciesDavid Tepper Gets Defensive. Is it Time to Get Out of The Stock Market?


Macro NewsChina Margin Debt Hits 8-Week High, Japan Pumps’n’Dumps As Kyle Bass Fears Looming EM Banking CrisisAre US – Russian Relations A Zero-Sum Game?US and Russia have launched direct talks on the conflict in SyriaYuan Drops as PBOC Cuts Reference Rate by Most Since DevaluationCould the market crash like 1987?—put volume spike argues low is nearCTAs NewsRed Rock Just Published Report About The Trend Following Landscape & How CTAs’ Performance Must Be AnalyzedHow to Implement Dual Momentum for non-US InvestorsDo Commodity Trading Advisors (CTAs) Really Provide Crisis Alpha, Equity Hedge and Are Long Volatility?





















Bizapedia.com - Human Validation
















COMPANIESPEOPLEPRODUCTS/SERVICESTRADEMARKSADDRESSESPHONE BOOK




            Our system has detected a high number of page requests from your IP Address, please prove to us that you are a human to continue using our website.
        
























                            Please send me to the search subscription offer page after I successfully answer the word challenge.
                        









BIZAPEDIAPRO SEARCHPerform unlimited searches via ouradvanced search form withBizapedia Pro Search.FIND OUT MORE >BIZAPEDIAPRO DATABuild custom data listsfor one or many stateswith Bizapedia Pro Data.FIND OUT MORE >


Copyright © 2012-2017 · Bizapedia.com · All rights reserved.BlogPro SearchPro APIContact UsTerms of UsePrivacy PolicySitemapDesktop Version























 





Insider Trading - Aisling Capital III Lp - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Aisling Capital III Lp





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-07-06Purchase
2016-07-065:10 pm
Syros Pharmaceuticals Inc.
SYRS
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
400,000
$12.5
$5,000,000
908,565(Direct)
View


2016-05-17Purchase
2016-05-194:24 pm
Loxo Oncology Inc.
LOXO
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
232,558
$21.5
$4,999,997
4,028,920(Direct)
View


2015-12-11Purchase
2015-12-156:28 pm
Loxo Oncology Inc.
LOXO
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
200
$27.5
$5,500
3,796,362(Direct)
View


2015-12-09Purchase
2015-12-094:47 pm
T2 Biosystems Inc.
TTOO
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
307,692
$9.75
$2,999,997
2,830,992(Indirect)
View


2015-11-17Purchase
2015-11-195:34 pm
Loxo Oncology Inc.
LOXO
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
265,000
$26.5
$7,022,500
3,796,182(Direct)
View


2015-11-12Purchase
2015-11-165:16 pm
Loxo Oncology Inc.
LOXO
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
78,669
$27.65
$2,175,023
3,531,182(Direct)
View


2015-01-27Purchase
2015-01-295:10 pm
Versartis Inc.
VSAR
Aisling Capital III LpAisling Capital Partners III LLCAisling Capital Partners III LpElms StevePurcell Dennis JSchiff Andrew N10% Owner
145,000
$17.25
$2,501,250
2,139,568(Indirect)
View


2015-01-23Purchase
2015-01-274:25 pm
Agile Therapeutics Inc
AGRX
Aisling Capital III LpAisling Capital Partners III LLCAisling Capital Partners III LpElms StevePurcell Dennis JSchiff Andrew NDirector10% Owner
811,966
$5.85
$4,750,001
2,983,797(Indirect)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-07-06Conversion
2016-07-065:10 pm
N/AN/A
Syros Pharmaceuticals Inc.
SYRS
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
508,565
$0
908,565(Direct)
View


2016-07-06Conversion
2016-07-065:10 pm
N/AN/A
Syros Pharmaceuticals Inc.
SYRS
Aisling Capital III LpAisling Capital Partners III LpAisling Capital Partners III LLCElms SteveSchiff Andrew NPurcell Dennis J10% Owner
1,907,122
$0
908,565(Direct)
View


2016-06-02Other
2016-06-034:55 pm
N/AN/A
Agile Therapeutics Inc
AGRX
Aisling Capital III LpAisling Capital Partners III LLCAisling Capital Partners III LpElms StevePurcell Dennis JSchiff Andrew N10% Owner
400,000
$0
2,583,797(Indirect)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Tue, 25 Jul 2017 10:36:20 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  








 







Aisling Capital LLC :: Law360
































Search




Advanced Search

Take a Free Trial | 
					Sign In






















 Close


Law360 In-Depth
Law360 UK
Adv. Search & Platform Tools
Browse all sections 
Banking
Bankruptcy
Class Action
Competition
Employment
Energy
Expert Analysis
Insurance
Intellectual Property
Product Liability
Securities
Rankings
Law360's MVPs
Glass Ceiling Report
Global 20
Law360 400
Diversity Snapshot
Practice Group Partner Rankings
Practice Groups of the Year
Pro Bono Firms of the Year
Rising Stars
Trial Aces
Site Menu
Join the Law360 team
Search legal jobs
Learn more about Law360
Read testimonials
Contact Law360
Sign up for our newsletters
Site Map
Help













Aisling Capital LLC


 News & Case Alert  on Aisling Capital LLC



Financial » Asset Management » Aisling Capital LLC






Menu options for Aisling Capital LLC 


Everything »
News & Analysis »
New Cases »
New PTAB Cases »
New TTAB Cases »
Case Activity »
Outside Counsel »


                Data on cases, clients, outside counsel and individual attorneys collected from active federal civil cases. Reflects only recently published court data; not intended to be exhaustive. Not responsible for errors in court dockets.
            






×
Please assign a name to this alert






Save Alert
Cancel










News (3)


January 17, 2017
SEC Fines Pershing Square, Others For Pay-To-Play Violations
.... They were Adams Capital Management, Aisling Capital, Alta Communications, Commonwealth Venture...


January  5, 2017
Fenwick Guides Cancer Biotech Loxo's $120M Follow-On
..., Loxo's largest shareholder is an affiliate of Aisling Capital, an investment firm focused on the life...


July 31, 2015
10 IPOs Targeting $1.4B Ready To Rock 1st Week Of August
..., including Longitude Venture Partners II LP, Aisling Capital III LP and Foresite Capital Fund II LP, an...


Cases (0)

No results

PTAB Cases (0)

No results

TTAB Cases (0)

No results


To view all the results and drill down deeper, take a free trial now.



Try Law360 FREE for seven days
Already a subscriber? Click here to login
















×
Already have access? Click here to login



Get instant access to the one-stop news source for business lawyers
Register Now!




Get instant access to the one-stop news source for business lawyers













Email (Professional email required)






First Name



Last Name







PLEASE NOTE: A verification email will be sent to your address before you can access your trial.


Password (at least 6 characters required)



Confirm Password







Select at least one primary interest:


 Aerospace & Defense
										

 Appellate
										

 Asset Management
										

 Automotive
										

 Banking
										

 Bankruptcy
										

 California
										

 Capital Markets
										

 Class Action
										

 Commercial Contracts
										

 Competition
										

 Consumer Protection
										

 Corporate
										

 Cybersecurity & Privacy
										

 Delaware
										

 Employment
										

 Energy
										

 Environmental
										

 Financial Services Uk
										

 Florida
										

 Food & Beverage
										

 Government Contracts
										

 Health
										

 Hospitality
										

 Illinois
										

 Immigration
										

 Insurance
										

 Insurance Uk
										

 Intellectual Property
										

 International Arbitration
										

 International Trade
										

 Law360 In Depth
										

 Legal Ethics
										

 Life Sciences
										

 Media & Entertainment
										

 Medical Malpractice
										

 Mergers & Acquisitions
										

 Native American
										

 New Jersey
										

 New York
										

 Pennsylvania
										

 Private Equity
										

 Product Liability
										

 Project Finance
										

 Public Policy
										

 Real Estate
										

 Retail & E Commerce
										

 Securities
										

 Sports
										

 Tax
										

 Technology
										

 Telecommunications
										

 Texas
										

 Transportation
										

 Trials
										

 White Collar
										





Register




Already have access?




Email:



Password:

Forgot your password?


Remember login



Sign In



















Aisling Capital Raises $650 Million for Third Fund - PE Hub

























































SUBSCRIBE TO PE HUB WIRE
Join over 60,000 of your peers
Get the must-read email for PE/VC professionals delivered to your inbox daily
        — for free!







US Edition (daily)



Canada Edition (weekly)


We will not send you spam, and we don't share your email address with 3rd parties.


I accept the Terms and Conditions




SUBSCRIBE YES! No






RegisterSign in



A Community for Professionals in Private Capital



































Aisling Capital Raises $650 Million for Third Fund


January 8, 2009
By PEHub Administrator







Aisling Capital has closed its third fund with $650 million in capital commitments. The New York-based venture firm focuses on the life sciences and healthcare sectors. It had raised $550 million for its second fund in 2005.

 
PRESS RELEASE
Aisling Capital announced today that it raised US$650 million in committed capital for its newest life sciences fund, Aisling Capital III, LP. Aisling Capital will invest its third fund primarily in companies developing pharmaceutical, biopharmaceutical and medical products, as well as in businesses that provide drug development, manufacturing and other important services to the healthcare industry. With a total of over US$1.6 billion in committed capital under management, the Aisling Capital team will also continue to manage the Perseus-Soros BioPharmaceutical Fund, LP and Aisling Capital II, LP. 





 
“We appreciate the support of our existing and new limited partners, particularly during these times of market turbulence,” commented Dennis Purcell, Senior Managing Partner of Aisling Capital. Mr. Purcell added: “We believe the next several years will be a critical period for the life sciences industry, in which multiple forces will converge to create opportunities for the prepared investor.”
 
The Aisling Capital team is comprised of individuals with a combination of clinical, transactional, operational and capital markets expertise, complemented by extensive networks in the life sciences industry. The team is led by Managing Partners Dennis Purcell, Steve Elms and Andrew Schiff, M.D. and newly promoted Partners Dov Goldstein, M.D., Anthony Sun, M.D. and Brett Zbar, M.D. Additionally, Josh Bilenker, M.D. has been promoted to Principal.
  





About Aisling Capital
 
Aisling Capital is a dedicated life sciences private equity firm with over US$1.6 billion under management. Headquartered in New York, Aisling Capital invests in both private and public companies utilizing a wide variety of investment structures. The Aisling Capital team’s combination of clinical, operational and financial experience allows the firm to identify, execute and realize investments across the life sciences industry.
 
Web site: http://www.aislingcapital.com
 
 




DON'T MISS OUT! Meet new and diverse managers in private equity, venture capital and real estate at the third Emerging Manager Connect East at New York City's Harvard Club. CLICK HERE FOR DETAILS!  









Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:


First Name:



Last Name:



Email Address:




US Edition (daily)



Canada Edition (weekly)


We will not send you spam, and we don't share your email address with 3rd parties.


I accept the Terms and Conditions









You are now subscribed to the PEHub Wire and Top Stories of the Week newsletters. 




Buyouts Insider/Argosy Group LLC produces several free newsletters that are sent directly to the email you provide at registration (namely, PE Hub Wire, PE Hub Canada Wire, PE Hub Wire Top Story of the Week, Buyouts Daily, and VCJ Alert). To enable us to keep providing these services free of charge, we reserve the right to contact you with special invitations to sample or purchase private equity-related products. 
By submitting this free subscription request for any of these products, you are also consenting to this communication. Should you ever wish to unsubscribe from a particular communication you may activate the unsubscribe mechanism at the bottom of the email. This will discontinue both the special invitations mentioned previously, as well as your subscription to the weekly newsletter. The information you provide will be safeguarded by Argosy Group LLC/Buyouts Insider. The company’s subsidiaries may use it to keep you informed of relevant products and services. We occasionally allow reputable companies outside of the company to mail details of products which may be of interest to you. As an international group, we may transfer your data on a global basis for the purposes indicated above. 
WE WILL NEVER SHARE YOUR EMAIL OR CONTACT DETAILS WITH ANY OUTSIDE COMPANY HOWEVER.

			    Should you have any questions please do not hesitate to contact us: [email protected].
	    	

 




Top Posts New oil and gas company Native racks up $140 mln
by Iris Dorbian

Bain Capital Double Impact funds two companies
by Iris Dorbian

MidOcean to sell Water Pik for $1 bln
by Luisa Beltran

Carlyle to invest in ZeroChaos
by Luisa Beltran

The PE HUB Podcast, Episode Two
by Staff Report

Awake Security nabs over $30 mln from Greylock and Bain Capital Ventures
by Iris Dorbian

Thoma Bravo to sell Sparta Systems to New Mountain
by Iris Dorbian

KKR to buy Nature’s Bounty from Carlyle
by Luisa Beltran

 
































Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











LD Products 10% Coupon Code and Up to 78% Off Printer Ink - LD Products



























We detected that your JavaScript seem to be disabled.
You must have JavaScript enabled in your browser to utilize the functionality of this website.





Tax Season Sale 15% Off Ink and Toner*
*Shop Now




 Quick Reorder
 Track Order
 Government

 My Printers




 Help
 888-321-2552


Create Account or

Sign In

















Free Shipping on all orders over $50†
Lifetime 100% Satisfaction Guarantee



 Free Shipping on orders over $50†
 Low Flat Rate Shipping - only $4.95 on orders under 50†
 Multiple Fulfillment Centers - so you get your order faster!
Orders placed before 4pm usually ship the same day!


†Applies to orders delivered to the contiguous U.S.
Close
Learn More




Reliability for a lifetime - All of our LD brand compatible ink and toner cartridges are backed by a lifetime guarantee
Verified Excellence - Our cartridges have been tested for performance, quality and page yield, so you know you are getting the absolute best product available.
Your Happiness Matters - In the event that you are dissatisfied with your purchase, simply let us know - we'll do our best to make it right.


Close
Learn More



 








 Special Offers








0 items









Ink & Toner
Office Supplies
Paper
Cleaning & Breakroom
Technology
Office Furniture






Featured Ink & Toner Brands
All Categories 

HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung



More Ink & Toner Brands

Konica
Pitney Bowes
Kyocera
Ricoh
Kodak
Sharp
Okidata
Toshiba
Panasonic
Refill Kits





Featured Office Supply Categories
All Categories 

Writing & Correction
General Supplies
Binders & Accessories
Filing Supplies
Envelopes & Forms
Calendars & Planners
Boards & Easels
Desk Organizers








More Office Supply Categories

Bags & Travel Accessories
Mailing & Shipping
Storage & Organizers
Tools & Equipment
Cash Handling
Labeling & Labeling Systems
Teaching & Art





Featured Paper Categories
All Categories 

Copy & Multi-use Paper
Notebooks, Pads & Filler Paper
Adhesive Note Pads
Photo Paper
Brochure & Specialty Paper
Cards & Stationary
Colored Paper
Wide Format Paper










Featured Cleaning & Breakroom Categories
All Categories 

Cleaning Supplies
Cleaning Equipment
Breakroom Supplies
Healthcare Supplies
Safety & Security
Facility Supplies
Climate Control










Featured Technology Categories
All Categories 

Printers
Office Machines & Electronics
Power & Backup
Network & Cables
3D Printing
Peripherals & Memory
Drives & Media
Shredders & Accessories








More Technology Categories

Audio Video Players
Computer Accessories
Radio & Mobile Technology
Software & Utilities
Cameras & Scanners
Ink Refill Kits
Telephone & Communication
Multimedia Players
Displays & Digital Projectors





Featured Office Furnitures Categories
All Categories 

Furniture Collections, Desks & Tables
Chairs, Chair Mats & Accessories
Office Decor & Lighting
Armoires & Bookcases
Filing, Storage & Accessories
Carts & Stands
Furniture Accessories
Panel Systems & Accessories















Menu
Call





Reorder
Cart













Ink & Toner 


Office Supplies 





HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica

Shop All Printer Brands 



Office Supplies
Paper
Cleaning
Technology
Office Furniture




 




Ink & Toner 
Office Supplies 
Paper 
Cleaning & Breakroom 
Technology 
Office Furniture 
My Printers
Sign In
Track your Order
Create Account
Help
 Special Offers



 Back

General Office Supplies
Ink & Toner
HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica
Shop All Printer Brands












10% OFF
Ink & Toner*
Plus Free Shipping on All Orders Over $50
Coupon Code 10LDP Applied
*Expires 6/30/17 Excludes OEM items. **Applies to orders delivered to the contiguous U.S.
*Scroll down for details


Find Printer Supplies Fast, Easy, & Hassle Free
Ink & Toner Finder






Select a Printer Brand


Select a PRINTER BRAND
 Top Brands
Brother
Canon
Epson
Hewlett Packard (HP)
Lexmark
Xerox
 All Brands A-Z
ACOM
AMT
Amano
AstroJet
Birmy Graphics
Brother
Bryce
Canon
Casio
Compaq
Computer Language RES
CopyStar
DEC
DataProducts
Dell
Dymo
Eicon Laser
Electronic Forms
Epson
Gestetner
Hasler
Hewlett Packard (HP)
IBM InfoPrint
Imagen
Imagistics
Interface Systems
Kodak
Konica-Minolta
Kyocera-Mita
Lanier
Lasermaster
Lexmark
Mimaki
Muratec
Mutoh
NEC
NashuaTEC
NeoPost
Newgen
North Atlantic 
Oce
Okidata
Olivetti
Olympia
Panasonic
Pitney Bowes
Primera
Printronix
Rena
Ricoh
Riso
Risograph
Roland
Samsung
Savin
Secap
Sharp
Sindoh
Star Micronics
TallyGenicom
Tandem
Telenorma TENOFAX
Texas Instruments
Toshiba
Xerox



Brother
Canon
Epson
Hewlett Packard (HP)
Lexmark
Xerox
ACOM
AMT
Amano
AstroJet
Birmy Graphics
Brother
Bryce
Canon
Casio
Compaq
Computer Language RES
CopyStar
DEC
DataProducts
Dell
Dymo
Eicon Laser
Electronic Forms
Epson
Gestetner
Hasler
Hewlett Packard (HP)
IBM InfoPrint
Imagen
Imagistics
Interface Systems
Kodak
Konica-Minolta
Kyocera-Mita
Lanier
Lasermaster
Lexmark
Mimaki
Muratec
Mutoh
NEC
NashuaTEC
NeoPost
Newgen
North Atlantic 
Oce
Okidata
Olivetti
Olympia
Panasonic
Pitney Bowes
Primera
Printronix
Rena
Ricoh
Riso
Risograph
Roland
Samsung
Savin
Secap
Sharp
Sindoh
Star Micronics
TallyGenicom
Tandem
Telenorma TENOFAX
Texas Instruments
Toshiba
Xerox






Select a PRINTERFAMILY


Select a PRINTER FAMILY







Select a PRINTER MODEL


Select a PRINTER MODEL




submit


Shop Ink & Toner From These Top Printer Brands
Shop by Printer Brand


HP


HP OfficeJet Pro 8600
HP OfficeJet Pro 8610
HP Envy 4500

Shop HP Ink


Canon


Canon PIXMA MX922
Canon PIXMA MG2520
Canon PIXMA MG2920

Shop Canon Ink


Epson


Epson WorkForce WF-3620
Epson WorkForce WF-3640
Epson WorkForce WF-2650

Shop Epson Ink


Brother


Brother MFC-J485DW
Brother MFC-J870DW
Brother MFC-J470DW

Shop Brother Ink


Lexmark


Lexmark X5650
Lexmark Prospect Pro205
Lexmark Pro715

Shop Lexmark Ink


Dell


Dell V525W
Dell H625cdw
Dell C1660w Color

Shop Dell Ink


Xerox


Xerox Phaser 6500
Xerox WorkCentre 6605
Xerox WorkCentre 6027

Shop Xerox Ink


Samsung


Samsung Xpress C410W
Samsung Xpress M2070FW
Samsung Xpress C460FW

Shop Samsung Ink


Konica-Minolta


Konica bizhub C554e
Konica bizhub C454e
Konica PagePro 1390MF

Shop Konica Ink


Okidata


Okidata Microline 320 Turbo
Okidata MB472w
Okidata OKI MC362W

Shop Okidata Ink



Shop All Printer Brands 





 





 























        Adding to Cart...
    



                        Added to Cart
                        


                Add  to Get Free Shipping*


Your order qualifies for Free Shipping*








Price



Qty: 
Subtotal







                                *Free shipping on orders over $50 to the contiguous U.S. Orders placed before 4pm PST typically ship the same day.
                            





Cart Summary Edit Cart



Items in Cart:



Estimated Shipping (Contiguous U.S.)



Ships Same Day!*
Coupon will be applied in shopping cart
View Cart
Continue Shopping



Customers Also Bought




















Other Social Login




Facebook Sign in




 
Google Sign in




 
Linkedin Sign in









 







Quick Reorder Login - LD Products




























We detected that your JavaScript seem to be disabled.
You must have JavaScript enabled in your browser to utilize the functionality of this website.





Tax Season Sale 15% Off Ink and Toner*
*Shop Now




 Quick Reorder
 Track Order
 Government

 My Printers




 Help
 888-321-2552


Create Account or

Sign In

















Free Shipping on all orders over $50†
Lifetime 100% Satisfaction Guarantee



 Free Shipping on orders over $50†
 Low Flat Rate Shipping - only $4.95 on orders under 50†
 Multiple Fulfillment Centers - so you get your order faster!
Orders placed before 4pm usually ship the same day!


†Applies to orders delivered to the contiguous U.S.
Close
Learn More




Reliability for a lifetime - All of our LD brand compatible ink and toner cartridges are backed by a lifetime guarantee
Verified Excellence - Our cartridges have been tested for performance, quality and page yield, so you know you are getting the absolute best product available.
Your Happiness Matters - In the event that you are dissatisfied with your purchase, simply let us know - we'll do our best to make it right.


Close
Learn More



 








 Special Offers








0 items









Ink & Toner
Office Supplies
Paper
Cleaning & Breakroom
Technology
Office Furniture






Featured Ink & Toner Brands
All Categories 

HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung



More Ink & Toner Brands

Konica
Pitney Bowes
Kyocera
Ricoh
Kodak
Sharp
Okidata
Toshiba
Panasonic
Refill Kits





Featured Office Supply Categories
All Categories 

Writing & Correction
General Supplies
Binders & Accessories
Filing Supplies
Envelopes & Forms
Calendars & Planners
Boards & Easels
Desk Organizers








More Office Supply Categories

Bags & Travel Accessories
Mailing & Shipping
Storage & Organizers
Tools & Equipment
Cash Handling
Labeling & Labeling Systems
Teaching & Art





Featured Paper Categories
All Categories 

Copy & Multi-use Paper
Notebooks, Pads & Filler Paper
Adhesive Note Pads
Photo Paper
Brochure & Specialty Paper
Cards & Stationary
Colored Paper
Wide Format Paper










Featured Cleaning & Breakroom Categories
All Categories 

Cleaning Supplies
Cleaning Equipment
Breakroom Supplies
Healthcare Supplies
Safety & Security
Facility Supplies
Climate Control










Featured Technology Categories
All Categories 

Printers
Office Machines & Electronics
Power & Backup
Network & Cables
3D Printing
Peripherals & Memory
Drives & Media
Shredders & Accessories








More Technology Categories

Audio Video Players
Computer Accessories
Radio & Mobile Technology
Software & Utilities
Cameras & Scanners
Ink Refill Kits
Telephone & Communication
Multimedia Players
Displays & Digital Projectors





Featured Office Furnitures Categories
All Categories 

Furniture Collections, Desks & Tables
Chairs, Chair Mats & Accessories
Office Decor & Lighting
Armoires & Bookcases
Filing, Storage & Accessories
Carts & Stands
Furniture Accessories
Panel Systems & Accessories















Menu
Call





Reorder
Cart













Ink & Toner 


Office Supplies 





HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica

Shop All Printer Brands 



Office Supplies
Paper
Cleaning
Technology
Office Furniture




 




Ink & Toner 
Office Supplies 
Paper 
Cleaning & Breakroom 
Technology 
Office Furniture 
My Printers
Sign In
Track your Order
Create Account
Help
 Special Offers



 Back

General Office Supplies
Ink & Toner
HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica
Shop All Printer Brands


















 





















Adding to Cart...




Added to Cart



Add  to Get Free Shipping*


Your order qualifies for Free Shipping*








Price



Qty: 
Subtotal







*Free shipping on orders over $50 to the contiguous U.S. Orders placed before 4pm PST typically ship the same day.






Cart Summary Edit Cart



Items in Cart:



Estimated Shipping (Contiguous U.S.)



Ships Same Day!*
Coupon will be applied in shopping cart
View Cart
Continue Shopping



Customers Also Bought

















Other Social Login




Facebook Sign in




 
Google Sign in




 
Linkedin Sign in
















LD Products 10% Coupon Code and Up to 78% Off Printer Ink - LD Products



























We detected that your JavaScript seem to be disabled.
You must have JavaScript enabled in your browser to utilize the functionality of this website.





Tax Season Sale 15% Off Ink and Toner*
*Shop Now




 Quick Reorder
 Track Order
 Government

 My Printers




 Help
 888-321-2552


Create Account or

Sign In

















Free Shipping on all orders over $50†
Lifetime 100% Satisfaction Guarantee



 Free Shipping on orders over $50†
 Low Flat Rate Shipping - only $4.95 on orders under 50†
 Multiple Fulfillment Centers - so you get your order faster!
Orders placed before 4pm usually ship the same day!


†Applies to orders delivered to the contiguous U.S.
Close
Learn More




Reliability for a lifetime - All of our LD brand compatible ink and toner cartridges are backed by a lifetime guarantee
Verified Excellence - Our cartridges have been tested for performance, quality and page yield, so you know you are getting the absolute best product available.
Your Happiness Matters - In the event that you are dissatisfied with your purchase, simply let us know - we'll do our best to make it right.


Close
Learn More



 








 Special Offers








0 items









Ink & Toner
Office Supplies
Paper
Cleaning & Breakroom
Technology
Office Furniture






Featured Ink & Toner Brands
All Categories 

HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung



More Ink & Toner Brands

Konica
Pitney Bowes
Kyocera
Ricoh
Kodak
Sharp
Okidata
Toshiba
Panasonic
Refill Kits





Featured Office Supply Categories
All Categories 

Writing & Correction
General Supplies
Binders & Accessories
Filing Supplies
Envelopes & Forms
Calendars & Planners
Boards & Easels
Desk Organizers








More Office Supply Categories

Bags & Travel Accessories
Mailing & Shipping
Storage & Organizers
Tools & Equipment
Cash Handling
Labeling & Labeling Systems
Teaching & Art





Featured Paper Categories
All Categories 

Copy & Multi-use Paper
Notebooks, Pads & Filler Paper
Adhesive Note Pads
Photo Paper
Brochure & Specialty Paper
Cards & Stationary
Colored Paper
Wide Format Paper










Featured Cleaning & Breakroom Categories
All Categories 

Cleaning Supplies
Cleaning Equipment
Breakroom Supplies
Healthcare Supplies
Safety & Security
Facility Supplies
Climate Control










Featured Technology Categories
All Categories 

Printers
Office Machines & Electronics
Power & Backup
Network & Cables
3D Printing
Peripherals & Memory
Drives & Media
Shredders & Accessories








More Technology Categories

Audio Video Players
Computer Accessories
Radio & Mobile Technology
Software & Utilities
Cameras & Scanners
Ink Refill Kits
Telephone & Communication
Multimedia Players
Displays & Digital Projectors





Featured Office Furnitures Categories
All Categories 

Furniture Collections, Desks & Tables
Chairs, Chair Mats & Accessories
Office Decor & Lighting
Armoires & Bookcases
Filing, Storage & Accessories
Carts & Stands
Furniture Accessories
Panel Systems & Accessories















Menu
Call





Reorder
Cart













Ink & Toner 


Office Supplies 





HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica

Shop All Printer Brands 



Office Supplies
Paper
Cleaning
Technology
Office Furniture




 




Ink & Toner 
Office Supplies 
Paper 
Cleaning & Breakroom 
Technology 
Office Furniture 
My Printers
Sign In
Track your Order
Create Account
Help
 Special Offers



 Back

General Office Supplies
Ink & Toner
HP
Canon
Epson
Brother
Lexmark
Dell
Xerox
Samsung
Okidata
Konica
Shop All Printer Brands












10% OFF
Ink & Toner*
Plus Free Shipping on All Orders Over $50
Coupon Code 10LDP Applied
*Expires 6/30/17 Excludes OEM items. **Applies to orders delivered to the contiguous U.S.
*Scroll down for details


Find Printer Supplies Fast, Easy, & Hassle Free
Ink & Toner Finder






Select a Printer Brand


Select a PRINTER BRAND
 Top Brands
Brother
Canon
Epson
Hewlett Packard (HP)
Lexmark
Xerox
 All Brands A-Z
ACOM
AMT
Amano
AstroJet
Birmy Graphics
Brother
Bryce
Canon
Casio
Compaq
Computer Language RES
CopyStar
DEC
DataProducts
Dell
Dymo
Eicon Laser
Electronic Forms
Epson
Gestetner
Hasler
Hewlett Packard (HP)
IBM InfoPrint
Imagen
Imagistics
Interface Systems
Kodak
Konica-Minolta
Kyocera-Mita
Lanier
Lasermaster
Lexmark
Mimaki
Muratec
Mutoh
NEC
NashuaTEC
NeoPost
Newgen
North Atlantic 
Oce
Okidata
Olivetti
Olympia
Panasonic
Pitney Bowes
Primera
Printronix
Rena
Ricoh
Riso
Risograph
Roland
Samsung
Savin
Secap
Sharp
Sindoh
Star Micronics
TallyGenicom
Tandem
Telenorma TENOFAX
Texas Instruments
Toshiba
Xerox



Brother
Canon
Epson
Hewlett Packard (HP)
Lexmark
Xerox
ACOM
AMT
Amano
AstroJet
Birmy Graphics
Brother
Bryce
Canon
Casio
Compaq
Computer Language RES
CopyStar
DEC
DataProducts
Dell
Dymo
Eicon Laser
Electronic Forms
Epson
Gestetner
Hasler
Hewlett Packard (HP)
IBM InfoPrint
Imagen
Imagistics
Interface Systems
Kodak
Konica-Minolta
Kyocera-Mita
Lanier
Lasermaster
Lexmark
Mimaki
Muratec
Mutoh
NEC
NashuaTEC
NeoPost
Newgen
North Atlantic 
Oce
Okidata
Olivetti
Olympia
Panasonic
Pitney Bowes
Primera
Printronix
Rena
Ricoh
Riso
Risograph
Roland
Samsung
Savin
Secap
Sharp
Sindoh
Star Micronics
TallyGenicom
Tandem
Telenorma TENOFAX
Texas Instruments
Toshiba
Xerox






Select a PRINTERFAMILY


Select a PRINTER FAMILY







Select a PRINTER MODEL


Select a PRINTER MODEL




submit


Shop Ink & Toner From These Top Printer Brands
Shop by Printer Brand


HP


HP OfficeJet Pro 8600
HP OfficeJet Pro 8610
HP Envy 4500

Shop HP Ink


Canon


Canon PIXMA MX922
Canon PIXMA MG2520
Canon PIXMA MG2920

Shop Canon Ink


Epson


Epson WorkForce WF-3620
Epson WorkForce WF-3640
Epson WorkForce WF-2650

Shop Epson Ink


Brother


Brother MFC-J485DW
Brother MFC-J870DW
Brother MFC-J470DW

Shop Brother Ink


Lexmark


Lexmark X5650
Lexmark Prospect Pro205
Lexmark Pro715

Shop Lexmark Ink


Dell


Dell V525W
Dell H625cdw
Dell C1660w Color

Shop Dell Ink


Xerox


Xerox Phaser 6500
Xerox WorkCentre 6605
Xerox WorkCentre 6027

Shop Xerox Ink


Samsung


Samsung Xpress C410W
Samsung Xpress M2070FW
Samsung Xpress C460FW

Shop Samsung Ink


Konica-Minolta


Konica bizhub C554e
Konica bizhub C454e
Konica PagePro 1390MF

Shop Konica Ink


Okidata


Okidata Microline 320 Turbo
Okidata MB472w
Okidata OKI MC362W

Shop Okidata Ink



Shop All Printer Brands 





 





 























        Adding to Cart...
    



                        Added to Cart
                        


                Add  to Get Free Shipping*


Your order qualifies for Free Shipping*








Price



Qty: 
Subtotal







                                *Free shipping on orders over $50 to the contiguous U.S. Orders placed before 4pm PST typically ship the same day.
                            





Cart Summary Edit Cart



Items in Cart:



Estimated Shipping (Contiguous U.S.)



Ships Same Day!*
Coupon will be applied in shopping cart
View Cart
Continue Shopping



Customers Also Bought




















Other Social Login




Facebook Sign in




 
Google Sign in




 
Linkedin Sign in









 





